Kyle Bass Has Acorda IPRs Rejected

Earlier this week, the Patent Trial and Appeal Board decided to reject (i.e. not institute) a petition for inter partes review (IPR) filed by hedge fund manager Kyle Bass and his Coalition for Affordable Drugs on the grounds that the prior art presented was not publicly available information and thus could not be used to invalidate the patents. The IPR targeted two patents held by Acorda Therapeutics for their multiple sclerosis drug Ampryra.